Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
DCVax-L is a lung cancer vaccine composed of patient-derived dendritic cells that have been transduced with a patient tumor-specific antigen, potentially resulting in increased anti-tumor immunity (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DCVax-L||DCVax-Lung||DCVax-L is a lung cancer vaccine composed of patient-derived dendritic cells that have been transduced with a patient tumor-specific antigen, potentially resulting in increased anti-tumor immunity (PMID: 29843811).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||glioblastoma||not applicable||DCVax-L||Phase III||Actionable||In a Phase III trial, addition of DCVax-L to standard therapy resulted in a median overall survival (mOS) of 23.1 months in the intended to treat group (n=331) of patients with newly diagnosed glioblastoma, with a mOS of 34.7 months in patients with methylated MGMT (n?=?131) (PMID: 29843811; NCT00045968).||29843811|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02146066||Expanded access||DCVax-L||Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221||Available||USA||0|
|NCT03014804||Phase II||DCVax-L DCVax-L + Nivolumab||Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma||Withdrawn||USA||0|